These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16397271)

  • 21. Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.
    Eder IE; Haag P; Bartsch G; Klocker H
    Future Oncol; 2005 Feb; 1(1):93-101. PubMed ID: 16555979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
    Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
    Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
    Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An S296R mutation in the human androgen receptor causes activation of the receptor by non-androgenic steroids and stronger inhibition by the nuclear receptor corepressor N-coR.
    Li YD; Lu Y; Chen GC; Lu J
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1252-7. PubMed ID: 18637017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
    Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
    Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
    Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
    Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease.
    Duff J; Davies P; Watt K; McEwan IJ
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1098-102. PubMed ID: 17073759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five novel androgen receptor gene mutations associated with complete androgen insensitivity syndrome.
    Jääskeläinen J; Mongan NP; Harland S; Hughes IA
    Hum Mutat; 2006 Mar; 27(3):291. PubMed ID: 16470553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
    Bergerat JP; Céraline J
    Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
    Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
    Cohen MB; Rokhlin OW
    J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor decoy molecules block the growth of prostate cancer.
    Quayle SN; Mawji NR; Wang J; Sadar MD
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1331-6. PubMed ID: 17227854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.
    Alen P; Claessens F; Verhoeven G; Rombauts W; Peeters B
    Mol Cell Biol; 1999 Sep; 19(9):6085-97. PubMed ID: 10454556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hinge region of the androgen receptor plays a role in proteasome-mediated transcriptional activation.
    Tanner T; Claessens F; Haelens A
    Ann N Y Acad Sci; 2004 Dec; 1030():587-92. PubMed ID: 15659841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection.
    van de Wijngaart DJ; Dubbink HJ; Molier M; de Vos C; Jenster G; Trapman J
    Prostate; 2011 Feb; 71(3):241-53. PubMed ID: 20690138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Identification of a highly conserved domain that suppresses the DNA-binding domain-DNA interactions in the androgen receptor].
    Liu GZ; Wang H; Wang ZX
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 30(4):394-8. PubMed ID: 16190381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.
    Need EF; Scher HI; Peters AA; Moore NL; Cheong A; Ryan CJ; Wittert GA; Marshall VR; Tilley WD; Buchanan G
    Endocrinology; 2009 Jun; 150(6):2674-82. PubMed ID: 19282387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.